[18F] Flutemetamol

DRUG4 trials

Sponsors

GE Healthcare

Conditions

Alzheimer's DiseaseBrain Fibrillarab LevelsHealthyMild Cognitive ImpairmentNormal Pressure Hydrocephalus

Phase 2

Comparison of PET Amyloid Imaging in Japanese and Western Subjects

CompletedNCT02813070

GE HealthcareAlzheimer's Disease, Healthy, Mild Cognitive Impairment

Start: 2012-10-31End: 2013-05-31Updated: 2017-06-05

Phase 3

PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

CompletedNCT01053312

GE HealthcareNormal Pressure Hydrocephalus

Start: 2009-12-31End: 2010-08-31Updated: 2012-06-11

Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels

CompletedNCT01165554

GE HealthcareBrain Fibrillarab Levels

Start: 2010-05-31End: 2011-11-30Updated: 2013-12-04

Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects

CompletedNCT01265394

GE HealthcareHealthy

Start: 2010-12-31End: 2011-04-30Updated: 2013-07-02

Related Papers

Estimation of amyloid distribution by [<sup>18</sup>F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition.

2018-08-1944 citations

Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer’s disease, subjects with amnestic mild cognitive impairment and healthy volunteers

Annals of Nuclear Medicine2017-02-0812 citations

Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.

2016-12-1283 citations